Improved outcomes after allogenic hematopoietic stem cell transplantation with Fludarabine/Treosulfan for patients with myelodysplastic syndromes

Allogeneic hematopoietic stem cell transplantation (allo HCT) is the only known potentially curative treatment for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). However, outcomes are generally poor, with a significant risk of relapse or transplant-related mortality. Prognosis for transplanted MDS patients can be delineated by widely used clinical scores such as the Revised International Scoring System (IPSS-R). Overall survival (OS) at 5 years post transplantation ranges from 23% to 71% for patients with very-high and very-low risk IPSS-R scores, respectively [1].

Source: Biology of Blood and Marrow Transplantation - February 19, 2020 Category: Hematology Authors: Eileen Wedge, Henrik Sengel øv, Jakob Werner Hansen, Niels Smedegaard Andersen, Ida Schjoedt, Soeren Lykke Petersen, Brian Kornblit, Kirsten Grønbæk, Lone Smidstrup Friis Source Type: research